Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Status:
Completed
Trial end date:
2019-08-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a combination of drugs can help to treat this type of
cancer. One drug is a chemotherapy agent called paclitaxel (Taxol®). Paclitaxel will be given
every week through the vein. Although the weekly schedule of paclitaxel is not included in
the label, the schedule and dose of weekly paclitaxel have been studied and have been proven
to be more effective than an old standard schedule. The other two work against HER2. One is
called trastuzumab (Herceptin®) and it is commonly given to women with early HER2 positive
breast cancer or with advanced HER2 positive breast cancer that has spread to other parts of
the body. Trastuzumab will be given through the vein every 3 weeks (or every week at the
doctor's discretion). The third drug, pertuzumab, is an investigational drug. It has not been
approved by the Food and Drug Administration. It has been given in studies to over 800
people. It has been effective in treating HER2 positive breast cancer. Pertuzumab will be
given every 3 weeks through the vein. This study is looking at the effectiveness of these
three drugs together.